BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pradaxa dabigatran etexilate regulatory update

The U.K.'s NICE asked for additional information on the cost-effectiveness of Pradaxa dabigatran from Boehringer before recommending the drug to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. NICE asked for clarification on Pradaxa's cost-effectiveness compared with warfarin...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >